mRNA Flu Shots Race to Market
The journal Nature published a Review on October 12, 2021, reporting pharma companies are racing to apply messenger-RNA (mRNA) technology to influenza vaccines.
These companies hope new mRNA influenza vaccines will have better efficacy against seasonal flu.
Existing flu shots built around inactivated viruses or recombinant proteins typically offer 40–60% protection against infection each year.
The U.S. CDC publishes the adjusted vaccine effectiveness estimates for influenza seasons from 2004-2021 at this link.
And in some flu seasons, a third 'booster' vaccination is required as flu shots' wane' towards the end of the season.
But making mRNA vaccines against the flu might be more challenging than crafting ones against COVID-19.
For one thing, it's no sure thing that mRNA can effectively deliver the main antigen found in influenza vaccines.
The full Review is found at this link.